RUMORED BUZZ ON ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

The current work examined the potential of using ARV-825 and ABBV-744 to raise the effectiveness of tamoxifen or fulvestrant moreover palbociclib. ARV-825 was effective in each p53 wild-form (WT) breast tumor cells As well as in cells missing purposeful p53 either alone or in combination with tamoxifen, even though the effectiveness of ABBV-744 was